News from the HMI

HMI announces publication of the article for the first time describing Novel Cell Receptor System of Bacteria

New York, NY – October 5, 2022 – today announced the publication of a manuscript titled “Novel Prokaryotic System Employing Previously Unknown Nucleic Acid-Based Receptors” 

HMI announces publication of the article for the first time describing Novel Cell Receptor System of Eukaryotes

New York, NY – August 9, 2022 – today announced the publication of a manuscript titled “Novel Cell Receptor System of Eukaryotes Formed by Previously Unknown Nucleic Acid-Based Receptors” 

Dr. G.Tetz is an invited speaker at  Westchester Biotech Project To Present “Microbiome Based Strategy for Antibiotic Selection” February 10th, 2022

Dr. G.Tetz presented at  The Lancet Summit “Bacterial DNA promotes tau and beta-amyloid aggregation and is suggested as a novel therapeutic target for Alzheimer’s disease” December 14-16, 2021

New York, NY (December 16, 2022) – A New-York city-based Human Microbiology Institute presented “Bacterial DNA promotes tau and beta-amyloid aggregation and is suggested as a novel therapeutic target for Alzheimer’s disease” at the Lancet Summit: Presymptomatic Prevention and Treatment of Neurodegenerative Diseases.

Dr. G.Tetz is an invited speaker at the Interdisciplinary Nanoscience Center at Aarhus University “Novel non-coding functions of bacterial extracellular nucleic acids” October 1st, 2021

HMI presented at CHEST 2021 “ERADICATING PSEUDOMONAS PERSISTENCE IN ADULT PATIENTS WITH CYSTIC FIBROSIS WITH A NEW ALGORITHM OF ANTIBIOTIC SELECTION” October 16-20, 2021

New York, NY (October 20, 2022) – Human Microbiology Institute presented “ERADICATING PSEUDOMONAS PERSISTENCE IN ADULT PATIENTS WITH CYSTIC FIBROSIS WITH A NEW ALGORITHM OF ANTIBIOTIC SELECTION” at the CHEST 2021.

HMI presented at 44th European Cystic Fibrosis Conference “ERADICATING PSEUDOMONAS PERSISTENCE IN ADULT PATIENTS WITH CYSTIC FIBROSIS WITH A NEW ALGORITHM OF ANTIBIOTIC SELECTION” 9-12 June 2021

New York, NY (June 12, 2022) – Human Microbiology Institute presented their recent data “ERADICATING PSEUDOMONAS PERSISTENCE IN ADULT PATIENTS WITH CYSTIC FIBROSIS WITH A NEW ALGORITHM OF ANTIBIOTIC SELECTION” at the 44th European Cystic Fibrosis Conference.

Dr. G.Tetz is an invited speaker at  Antibiotics Webinar “Antibiotics vs. Phage Therapy” May 10th, 2021 Therapy

Dr. George Tetz, MD, PhD, Human Microbiology Institute, NY, USA, is an invited speaker at Antibiotics Webinar | Antibiotics vs. Phage Therapy 10 May 2021

This webinar is focused on the comparison and interplay between antibiotics and phage therapy. George Tetz, will be giving a talk on the ole pf phages as possible human pathogens.  https://www.mdpi.com/journal/antibiotics/events

HMI will be presenting our science at World Microbe Forum 2021

Abstract Title: Bacterial DNA Promotes Tau and Beta-amyloid Aggregation and Is Suggested as a Novel Therapeutic Target for Alzheimer’s Disease

Our abstract was accepted for an iPoster presentation at the #WorldMicrobeForum! Plan to see me online from June 20-24! Visit the website for details: https://bit.ly/3mLJcg1

HMI’s subsidiary TGV-Dx wins prestigious pediatric medical device competition focused on COVID-19-related technologies

New York, NY – July 22, 2020) – A New-York city-based start-up TGV-Dx was selected a winner in the special COVID-19 edition of the “Make Your Medical Device Pitch for Kids!” competition presented by FDA-sponsored National Capital Consortium for Pediatric Device Innovation. The competition focused on innovations in COVID-19-related pediatric medical devices that will improve children’s health care, with 16 finalists competing in a virtual pitch event for a share of $250,000 in total grant awards. TGV-Dx received a grant award as a result of their winning presentation